RPRX Volume Alert - RPRX 9.35 Repros Therapeutics Inc $RPRX

New Post Public Reply Private Reply Replies (0) Message Board

Nov 10, 2014 at 2:59 PM

RPRX Volume Alert - RPRX 9.35 Repros Therapeutics Inc $RPRX Hit a high of 9.65 Currently 11:15 Last price 9.35 -0.77 -7.61% With a day low of 8.55 and a current volume of 1,677,952.

RPRX Repros Therapeutics Inc Recent Headline News

Repros Therapeutics posts 3Q loss
Automated Insights - Mon Nov 10, 8:13AM CST
WOODLANDS, Texas (AP) _ Repros Therapeutics Inc. (RPRX) on Monday reported a loss of $7.4 million, or 32 cents per share, in its third quarter.
RPRX: 9.35 (-0.77)

Repros Therapeutics beats by $0.07
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 8:11AM CST

RPRX: 9.35 (-0.77)

Repros Therapeutics Inc.(R) Reports Third Quarter 2014 Financial Results
GlobeNewswire - Mon Nov 10, 8:00AM CST
Repros Therapeutics Inc. (Nasdaq:RPRX) today announced financial results for the third quarter ended September 30, 2014.
RPRX: 9.35 (-0.77)

Nasdaq stocks posting largest percentage increases
AP - Fri Nov 07, 5:08PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
SWIR: 35.64 (+1.74), PERI: 5.76 (+0.01), UNXL: 5.60 (+0.29), TREE: 47.40 (+0.37), SSRI: 4.77 (-0.43), STMP: 43.68 (+0.76), RPRX: 9.35 (-0.77), NYNY: 7.69 (-0.05), SHLD: 39.88 (-2.93), AREX: 10.38 (-0.35), PGNX: 5.86 (+0.49), ECYT: 6.13 (+0.10), SSO.TO: 5.44 (-0.46), SGMA: 7.27 (+0.06), SW.TO: 40.58 (+2.19), PLNR: 7.51 (+1.11)

Sears Soars Nearly +40% As REIT News Boosts Confidence
at The Street - Fri Nov 07, 2:42PM CST
Repros Therapeutics Inc (NASDAQ:RPRX), Sears Holdings Corp (NASDAQ:SHLD) and Allied Nevada Gold Corp. (NYSEMKT:ANV) are among the top-gaining billionaire stock picks of the day. On the losing end ar...
ANV: 1.08 (+0.03), AMSC: 1.18 (+0.01), RPRX: 9.35 (-0.77), SHLD: 39.88 (-2.93), STAY: 18.41 (+0.11)

Midday Gainers/Losers
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 11:52AM CST

ROKA: 3.47 (+0.47), NES: 8.56 (-0.72), FNGN: 31.05 (-0.34), FIVN: 4.91 (-0.17), MSON: 11.07 (-0.73), SLXP: 93.11 (+1.64), SUMR: 1.86 (-0.20), RPRX: 9.35 (-0.77), QTWO: 18.06 (-0.81), EV: 42.86 (-1.04), SHLD: 39.88 (-2.93), STAY: 18.41 (+0.11), PSIX: 68.40 (-0.75), BORN: 1.50 (+0.02), URRE: 2.47 (+0.53), ECOM: 18.28 (+0.43), ICPT: 175.00 (+2.41), SAEX: 4.50 (-0.42), VPCO: 1.80 (-0.14), SZYM: 3.61 (-0.02)

Repros Therapeutics (RPRX) Stock Skyrockets After Meeting with FDA About Androxal
at The Street - Fri Nov 07, 10:07AM CST
Shares of Repros Therapeutics (RPRX) soared in morning trading Friday after the biopharmaceutical company held what it called a "constructive meeting" with the FDA regarding its testosterone-boosting drug Androxal.
RPRX: 9.35 (-0.77)

Repros jumps after FDA meeting on Androxal NDA
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 9:20AM CST

RPRX: 9.35 (-0.77)

Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 8:14AM CST

BEBE: 2.43 (+0.03), ANET: 78.87 (+1.04), TKMR: 16.39 (-0.36), ORBC: 5.95 (+0.15), MDRX: 11.32 (-0.22), RMTI: 10.70 (+0.15), CTIC: 2.10 (-0.03), SHLD: 39.88 (-2.93), UBNT: 29.39 (+0.61), RIG: 29.28 (-0.43), KGC: 2.33 (-0.17), APT: 3.25 (-0.01), ANF: 28.50 (-1.00), MITK: 3.16 (+0.20), ZNGA: 2.47 (+0.04), CNET: 2.08 (-0.03), KING: 13.73 (+0.01), NETE: 1.44 (+0.02), SLXP: 93.11 (+1.64), RPRX: 9.35 (-0.77), NADL: 5.08 (-0.36), PGNX: 5.86 (+0.49), AVNR: 13.20 (+0.18), FSLR: 51.89 (+1.60), DVA: 74.55 (+0.06), NDLS: 24.57 (-0.25), ICPT: 175.00 (+2.41), AGIO: 80.28 (+8.22), PLNR: 7.51 (+1.11)

Repros Holds Constructive Meeting With FDA Regarding Androxal(R) NDA Filing
GlobeNewswire - Thu Nov 06, 3:21PM CST
-- No New Clinical Studies Requested
RPRX: 9.35 (-0.77)

Will Repros (RPRX) Miss Estimates This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 2:12PM CST
Repros Therapeutics Inc. (RPRX) has an earnings ESP of 0.00% and a Zacks Rank #4 (Sell).
MNK: 92.83 (+1.77), PBH: 31.40 (-1.39), RPRX: 9.35 (-0.77), HSP: 56.06 (-0.26)

63.7% Return Seen to Date on SmarTrend Repros Therapeutics Call (RPRX)
Comtex SmarTrend(R) - Mon Nov 03, 10:56AM CST
SmarTrend identified a Downtrend for Repros Therapeutics (NASDAQ:RPRX) on September 4th, 2014 at $17.86. In approximately 2 months, Repros Therapeutics has returned 63.72% as of today's recent price of $6.48.
RPRX: 9.35 (-0.77)

Technical Coverage of Pharma Stocks - Repros Therapeutics, Nektar Therapeutics, Akorn, AcelRx Pharma, and Pernix Therapeutics Holdings
PR Newswire - Mon Nov 03, 7:45AM CST
Investor-Edge has initiated coverage on the following equities: Repros Therapeutics Inc. (NASDAQ: RPRX), Nektar Therapeutics (NASDAQ: NKTR), Akorn Inc. (NASDAQ: AKRX), AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX), and Pernix Therapeutics Holdings Inc. (NASDAQ: PTX). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Friday, October 31, 2014, the NASDAQ Composite ended at 4,630.74, up 1.41%, the Dow Jones Industrial Average advanced 1.13%, to finish the day at 17,390.52, and the S&P 500 closed at 2,018.05, up 1.17%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 778.85, up 0.51%, with the index also advancing 10.60% in the previous three months. Register for your complimentary reports on these five stocks at:
ACRX: 5.95 (-0.09), PTX: 9.50 (+0.41), AKRX: 35.65 (-0.94), RPRX: 9.35 (-0.77), NKTR: 13.61 (+0.26)

Repros to Webcast Investor and Analyst Day on October 31st
GlobeNewswire - Mon Oct 27, 3:01PM CDT
Repros Therapeutics Inc.(Nasdaq:RPRX) today announced that it will host a live webcast of its Investor and Analyst Day that is being held in New York City on Friday, October 31, 2014 beginning at 7:30 a.m. Eastern Time.
RPRX: 9.36 (-0.76)

Biotech Stock Roundup: AbbVie Calls off Shire Acquisition, Will Amgen Consider Breakup? - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Oct 22, 10:18AM CDT
Will Amgen (AMGN) go the Abbott (ABT) way and split into two separate companies?
PCYC: 134.09 (+0.60), NPSP: 26.55 (-0.94), RPRX: 9.36 (-0.76), AMGN: 162.61 (+2.36), ABBV: 63.55 (+2.05), REGN: 384.88 (+7.04), CELG: 107.86 (+1.41)

SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Violations of Federal Securities Laws by the Board of Directors of Repros Therapeutics Inc. - RPRX
PR Newswire - Mon Oct 20, 12:33PM CDT
Levi & Korsinsky, LLP is investigating Repros Therapeutics Inc. ("Repros" or the "Company"

(NasdaqCM: RPRX) in connection with possible violations of federal securities laws.
RPRX: 9.36 (-0.76)

INVESTOR ALERT: Investigation of Repros Therapeutics Inc. Announced by Glancy Binkow & Goldberg LLP
Business Wire - Mon Oct 20, 9:36AM CDT
Glancy Binkow & Goldberg LLP announces that it is investigating potential claims on behalf of investors of Repros Therapeutics Inc. ("Repros Therapeutics" or the "Company"

(NASDAQ: RPRX) concerning possible violations of federal securities laws. The investigation focuses on certain statements issued by the Company concerning the Company's business and financial prospects.
RPRX: 9.36 (-0.76)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Innovent's IBI3001 Shows Promise in Phase 1 Trials

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Sac-TMT's Phase III Success Shifts Lung Cancer Paradigm

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...

Lilly's Olomorasib: New Data Sparks Hope for G12C NSCLC

New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...

DigitalXForce Shakes Up GRC: AI-Infused X-ROC Launch

Turning Risk Management on Its Head Well, here's a company not just tinkering around the edges but flipping the script on Governance, Risk, and Compliance (GRC) with their latest rollout: DigitalXForce and its X-ROC. Yeah, it's yet another acronym to juggle, but don't roll your eyes just yet. This AI-driven beast isn't about occasional boardroom reports. No sir, it's a...

TORRAS Cases Balance Protection with Slim Design for 2026

Are Slim iPhone Cases Really Protecting Your Investment? Anyone who's dropped a brand-new phone knows the pain of watching your investment smack the concrete. But hey, welcome to 2026, where Consumer365's latest rundown on iPhone protective gear turns the spotlight on TORRAS. These folks grabbed attention with their Q3 Air and Q3 Air Pro cases, crafted for iPhone 18 Pro...

Clarins Dazzles Austin with Skin Longevity Event

Clarins Takes Austin by Storm Under the vast Austin sky, something remarkable unfolded as Clarins transformed the scene with a flashy rooftop affair that screamed innovation and elegance. They weren’t just showing off fancy bottles of beauty potion; they were stirring the pot, merging science with a splash of high-end glitz. This wasn’t just another product pitch—it...

Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Dr. Boonipat Inspires Future Women Surgeons at Texas Tech

Sowing Surgical Seeds in Lubbock In Lubbock, Texas, something meaningful unfolded—an event the big market players would hardly blink at, but a significant step for the future of medicine. Led by Dr. Thanapoom "Mo" Boonipat, the founder of FacePlus Plastic Surgery Institute, a unique suturing workshop provided premed students at Texas Tech University hands-on experience...

Borr Drilling's Rig Sinks, Uncertainty Looms Offshore

Unexpected Turn of Events at Sea Now here's a gut-punch nobody saw coming. Borr Drilling Limited (NYSE and OSE: BORR) got hit hard when their Prospector 5 drilling rig went under the waves offshore Gabon. This ain't no desk job dilemma; we're talking about a real-life offshore catastrophe. It all went down on October 24, 2026, when the rig experienced a punch through...

Gildan Activewear Faces Legal Battle Over Alleged Fraud

Investor Alert: Gildan's Legal Showdown Alright, here's a twist you didn't see coming—or maybe you did if you've been tracking the ticker tapes like a hawk. Gildan Activewear Inc. (NYSE:GIL) is stuck in the kind of hot water that can scald the bottom line. The Stakes: Racing Towards December 14 Marked on your calendar, December 14, is a date of some significance if...